研究园简易版 · 经典书籍 · 期刊文章 · 有原文 · 完整版(可多选筛选、搜索) · 首页
2025 年 · Clinical Trials(临床试验)
173 篇,新的在前。点标题看作者和摘要。回到 2025 年
- Mendelian Randomization Methods for Causal Inference: Estimands, Identification and Inference · SiM · 2025-12-29 · 在第 1 页
- Censoring-robust estimation in fixed sample time-to-event clinical trials with adaptive randomization · Biometrics · 2025-12-19 · 在第 1 页
- Dynamic Prediction of Analysis Timing in Clinical Trials Using Joint Models of Longitudinal and Time‐to‐Event Data · SiM · 2025-12-14 · 在第 1 页
- Effects Among the Affected · SiM · 2025-12-11 · 在第 2 页
- Group‐Sequential Designs With an Externally‐Driven Change of Primary Endpoint · SiM · 2025-12-10 · 在第 2 页
- Doubly Robust Estimation and Sensitivity Analysis With Outcomes Truncated by Death in Multi‐Arm Clinical Trials · SiM · 2025-12-09 · 在第 2 页
- Joint time-to-event partial order continual reassessment method and Joint time-to-event Bayesian logistic regression model: Statistical designs for dual agent phase I/II dose finding studies with late-onset toxicity and activity outcomes · SMMR · 2025-12-05 · 在第 2 页
- Covariate‐Adjusted Group Sequential Comparisons of Survival Probabilities · SiM · 2025-12-05 · 在第 2 页
- Augmented binary method for basket trials (ABBA) · SMMR · 2025-12-05 · 在第 2 页
- Cluster‐Level Analyses to Estimate a Risk Difference in a Cluster Randomized Trial With Confounding Individual‐Level Covariates: A Simulation Study · SiM · 2025-12-04 · 在第 2 页
- Bayesian Integrated Learning of Longitudinal Dose‐Response Relationships via Decentralized Clinical Trials · SiM · 2025-12-03 · 在第 2 页
- Graph Based, Adaptive, Multiarm, Multiple Endpoint, Two‐Stage Designs · SiM · 2025-12-02 · 在第 3 页
- A common-cause principle for eliminating selection bias in causal estimands through covariate adjustment · AoS · 2025-12-01 · 在第 3 页
- Using Individualized Treatment Effects to Assess Treatment Effect Heterogeneity · SiM · 2025-11-27 · 在第 3 页
- Adaptive sample size re-estimation designs for a two-stage randomized trial with binary outcome · SMMR · 2025-11-27 · 在第 3 页
- A Tutorial for Propensity Score Weighting Methods Under Violations of the Positivity Assumption · SiM · 2025-11-27 · 在第 4 页
- Bayesian Prediction of Event Times Using Mixture Model for Blinded Randomized Controlled Trials · SiM · 2025-11-25 · 在第 4 页
- Optimality Considerations in Two‐Stage Biomarker‐Stratified Trials With Adaptive Enrichment · SiM · 2025-11-17 · 在第 4 页
- Regional Consistency Evaluation and Sample Size Calculation Under Two MRCTs · SiM · 2025-11-07 · 在第 4 页
- Estimation of Interventional Effects in Clinical Trials With a Repeatedly Measured Mediator · SiM · 2025-11-07 · 在第 4 页
- Using inverse probability of censoring weighting to estimate hypothetical estimands in clinical trials: Should we implement stabilisation, and if so how? · SMMR · 2025-10-31 · 在第 5 页
- Clarifying the role of the Mantel–Haenszel risk difference estimator in randomized clinical trials · Biometrics · 2025-10-31 · 在第 5 页
- Combined P ‐Value Functions for Compatible Effect Estimation and Hypothesis Testing in Drug Regulation · SiM · 2025-10-23 · 在第 5 页
- Specification of Estimands for Complex Disease Processes Using Multistate Models and Utility Functions · SiM · 2025-10-14 · 在第 6 页
- An Approach to Design Adaptive Clinical Trials With Time‐to‐Event Outcomes Based on a General Bayesian Posterior Distribution · SiM · 2025-10-09 · 在第 6 页
- Adaptive Biomarker‐Based Design for Early Phase Clinical Trials · SiM · 2025-10-09 · 在第 6 页
- Statistical inference for heterogeneous treatment effect with right-censored data from synthesizing randomized clinical trials and real-world data · Biometrics · 2025-10-08 · 在第 6 页
- Randomized optimal selection design for dose optimization · Biometrics · 2025-10-08 · 在第 6 页
- Implementing response-adaptive randomisation in stratified rare-disease trials: Design challenges and practical solutions · SMMR · 2025-10-06 · 在第 7 页
- Nothing to See Here? A Non-Inferiority Approach to Parallel Trends · SiM · 2025-09-30 · 在第 8 页
- Investigations of sharp bounds for causal effects under selection bias · SMMR · 2025-09-30 · 在第 8 页
- Augmented two-stage estimation for treatment switching in oncology trials: Leveraging external data for improved precision · SMMR · 2025-09-30 · 在第 8 页
- Analysis of Stepped‐Wedge Cluster Randomized Trials When Treatment Effects Vary by Exposure Time or Calendar Time · SiM · 2025-09-24 · 在第 8 页
- Response to Letter to the Editor “Comments on ‘Novel Non‐Linear Models for Clinical Trial Analysis With Longitudinal Data: A Tutorial Using SAS for Both Frequentist and Bayesian Methods’” · SiM · 2025-09-23 · 在第 8 页
- Designing Stepped Wedge Cluster Randomized Trials With a Baseline Measurement of the Outcome · SiM · 2025-09-23 · 在第 8 页
- Group Sequential Trial Design Using Stepwise Monte Carlo for Increased Flexibility and Robustness · SiM · 2025-09-22 · 在第 8 页
- Model‐Robust Standardization in Cluster‐Randomized Trials · SiM · 2025-09-18 · 在第 8 页
- The Estimand Framework in Diagnostic Accuracy Studies · SiM · 2025-09-17 · 在第 8 页
- Handling Missing Outcome Data in Cluster Randomized Trials With Both Individual‐ and Cluster‐Level Dropout · SiM · 2025-09-17 · 在第 8 页
- Towards Efficient Time‐to‐Event Dose‐Escalation Guidance of Multi‐Cycle Cancer Therapies · SiM · 2025-09-16 · 在第 8 页
- Impact of Endpoint Delay on the Efficiency of Multi Arm Multi Stage Trials · SiM · 2025-09-15 · 在第 8 页
- Power and Sample Size Calculation for Multivariate Longitudinal Trials Using the Longitudinal Rank Sum Test · SiM · 2025-09-14 · 在第 9 页
- Bayesian Adaptive Enrichment Design for Continuous Biomarkers · SiM · 2025-09-14 · 在第 9 页
- Using Confidence Distributions in Final and Interim Analyses for Single‐Arm Studies or Platform Trials Consisting of Single‐Arm Studies · SiM · 2025-09-09 · 在第 9 页
- Testing for Similarity of Dose Response in Multiregional Clinical Trials · SiM · 2025-09-08 · 在第 9 页
- A Bayesian Multi‐Factorial Design and Analysis for Estimating Combined Effects of Multiple Interventions in a Pragmatic Clinical Trial to Improve Dementia Care · SiM · 2025-09-07 · 在第 9 页
- Multiplicity Control in Oncology Clinical Trials With a Binary Surrogate Endpoint‐Based Drop‐The‐Losers Design · SiM · 2025-09-05 · 在第 9 页
- A robust Bayesian dose optimization design with backfill and randomization for phase I/II clinical trials · SMMR · 2025-09-05 · 在第 9 页
- Implementing response-adaptive designs when responses are missing: Impute or ignore? · SMMR · 2025-08-29 · 在第 9 页
- Exact power and sample size in clinical trials with two co-primary binary endpoints · SMMR · 2025-08-29 · 在第 9 页
- Long-Term Effect Estimation When Combining Clinical Trial and Observational Follow-Up Datasets · JASA · 2025-08-27 · 在第 10 页
- Testing and Estimation of Treatment Effects in Clinical Trials for Terminal and Nonterminal Events Subject to Competing Risks · SiM · 2025-08-22 · 在第 10 页
- Prior Effective Sample Size When Borrowing on the Treatment Effect Scale · SiM · 2025-08-22 · 在第 10 页
- The Cox Model With Adaptive Fused Group Bridge Penalty to Incorporate Historical Data Into the Analysis of Clinical Trials With an Application to BMT CTN 1101 · SiM · 2025-08-16 · 在第 10 页
- Cumulative Logit Ordinal Regression With Proportional Odds Under Nonignorable Missing Responses—Application to Phase III Trial · SiM · 2025-08-14 · 在第 10 页
- A Framework for Generating Realistic Synthetic Tabular Data in a Randomized Controlled Trial Setting · SiM · 2025-08-13 · 在第 10 页
- Selecting the optimal longitudinal cluster randomized design with a continuous outcome: Parallel-arm, crossover, or stepped-wedge · SMMR · 2025-08-11 · 在第 11 页
- Confidence Intervals for Adaptive Trial Designs II : Case Study and Practical Guidance · SiM · 2025-08-08 · 在第 11 页
- Confidence Intervals for Adaptive Trial Designs I: A Methodological Review · SiM · 2025-08-08 · 在第 11 页
- Novel Clinical Trial Design With Stratum‐Specific Endpoints and Global Test Methods for Rare Diseases With Heterogeneous Clinical Manifestations · SiM · 2025-08-07 · 在第 11 页
- Health Utility Survival for Randomized Clinical Trials: Extensions and Statistical Properties · SiM · 2025-08-07 · 在第 11 页
- Assessing Covariate Balance With Small Sample Sizes · SiM · 2025-08-07 · 在第 11 页
- A Statistical Method for Benefit–Risk Assessment in Clinical Trials · SiM · 2025-08-07 · 在第 11 页
- A note on response-adaptive randomization from a Bayesian prediction viewpoint · SMMR · 2025-08-06 · 在第 11 页
- Efficient randomized adaptive designs for multi-arm clinical trials · SMMR · 2025-07-30 · 在第 12 页
- To what extent is response-adaptive randomization used in clinical trials? A systematic review using Cortellis Regulatory Intelligence database · SMMR · 2025-07-24 · 在第 12 页
- Precision generalized phase I-II designs · Biometrics · 2025-07-24 · 在第 12 页
- Design and Analysis of N‐Of‐1 Trials That Incorporate Sequential Monitoring · SiM · 2025-07-21 · 在第 13 页
- An Integrated and Coherent Framework for Point Estimation and Hypothesis Testing With Concurrent Controls in Platform Trials · SiM · 2025-07-21 · 在第 13 页
- Design of egocentric network-based studies to estimate causal effects under interference · SMMR · 2025-07-17 · 在第 13 页
- An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties · SiM · 2025-07-17 · 在第 13 页
- Sample Size Calculations for Partially Clustered Trials · SiM · 2025-07-15 · 在第 14 页
- MARGO: Machine Learning‐Assisted Adaptive Randomization for Group Sequential Trials Based on Overlap Weights · SiM · 2025-07-15 · 在第 14 页
- Improve the Precision of Area Under the Curve Estimation for Recurrent Events Through Covariate Adjustment · SiM · 2025-07-15 · 在第 14 页
- Assessing Mediation in Cross‐Sectional Stepped Wedge Cluster Randomized Trials · SiM · 2025-07-15 · 在第 14 页
- A Note on the Sample Size Formula for a Win Ratio Endpoint · SiM · 2025-07-15 · 在第 14 页
- Model-based approach for two-stage group sequential or adaptive designs in bioequivalence studies using parallel and crossover designs · SMMR · 2025-07-13 · 在第 14 页
- Leveraging external data for testing experimental therapies with biomarker interactions in randomized clinical trials · Biometrika · 2025-07-10 · 在第 14 页
- Health utility adjusted survival: A composite endpoint for clinical trial designs · SMMR · 2025-07-09 · 在第 14 页
- Population-adjusted unanchored indirect comparisons of cancer therapies with borrowing of pan-tumor information · SMMR · 2025-07-04 · 在第 14 页
- Group sequential analysis of marked point processes: Plasma donation trials · SMMR · 2025-07-02 · 在第 15 页
- Power calculation for cross-sectional stepped wedge cluster randomized trials with a time-to-event endpoint · Biometrics · 2025-06-25 · 在第 15 页
- COCA: a randomized Bayesian design integrating dose optimization and component contribution assessment for combination therapies · Biometrics · 2025-06-24 · 在第 15 页
- Strategies to boost statistical efficiency in randomized oncology trials with primary time-to-event endpoints · SMMR · 2025-06-23 · 在第 15 页
- Optimal Allocation of Observations in Stepped‐Wedge and Other Cluster Studies With Correlated Cluster‐Period Effects · SiM · 2025-06-23 · 在第 15 页
- Design of platform trials with a change in the control treatment arm · Biometrics · 2025-06-20 · 在第 15 页
- Spatiotemporal effects on dengue incidence based on a large cluster randomized study · SMMR · 2025-06-19 · 在第 16 页
- Response adaptive randomisation in clinical trials: Current practice, gaps and future directions · SMMR · 2025-06-18 · 在第 16 页
- Permutation tests for detecting treatment effect heterogeneity in cluster randomized trials · SMMR · 2025-06-17 · 在第 16 页
- Testing for a General Changepoint in Medical and Psychometric Studies: Changes Detection and Sample Size Planning · SiM · 2025-06-13 · 在第 16 页
- On the finite-sample and asymptotic error control of a randomization-probability test for response-adaptive clinical trials · Biometrics · 2025-06-13 · 在第 16 页
- Design and Analysis of Group Sequential Trials for Repeated Measurements When Pipeline Data Occurs: A Tutorial · SiM · 2025-06-13 · 在第 16 页
- Futility Monitoring in Clinical Trials · SiM · 2025-06-11 · 在第 16 页
- Semiparametric Estimation of Relative Causal Effects in Randomized Controlled Trials With Noncompliance · SiM · 2025-06-07 · 在第 16 页
- Sample Size Assessment and Interim Analysis Strategies for Survival Trial Designs With Covariate‐Adaptive Randomization · SiM · 2025-06-07 · 在第 16 页
- Dynamic Information Borrowing From External Data in Clinical Trials: The Elastic Commensurate Prior Approach · SiM · 2025-06-05 · 在第 16 页
- BEAM: Bayesian Hybrid Design With Adaptive Sample Size Through Multisource Exchangeability Modeling · SiM · 2025-06-05 · 在第 17 页
- A Two‐Stage Method for Extending Inferences From a Collection of Trials · SiM · 2025-06-05 · 在第 17 页
- Predictive Probabilities Made Simple: A Fast and Accurate Method for Clinical Trial Decision‐Making · SiM · 2025-06-03 · 在第 17 页
- Posterior Predictive Design for Phase I Clinical Trials · JASA · 2025-06-03 · 在第 17 页
- A Seamless Hybrid Phase II/III Design With Bayesian Interim Subgroup Selection · SiM · 2025-06-03 · 在第 17 页
- Randomization‐Based Inference for MCP‐Mod · SiM · 2025-05-22 · 在第 18 页
- Confidence Intervals and Sample Size for the ICC in Two‐Way ANOVA Models · SiM · 2025-05-22 · 在第 18 页
- An Alternative Measure for Quantifying the Heterogeneity in Meta‐Analysis · SiM · 2025-05-22 · 在第 18 页
- Accounting for Carryover Toxicity in Phase I Clinical Trials with Intra‐Patient Dose Escalation · SiM · 2025-05-22 · 在第 18 页
- A Biomarker Signature‐Guided Clinical Trial Design for Precision Medicine · SiM · 2025-05-22 · 在第 18 页
- A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent Events · SiM · 2025-05-20 · 在第 18 页
- UNITED: A Unified Transparent and Efficient Phase I/II Trial Design for Dose Optimization Accounting for Ordinal Graded, Continuous and Mixed Toxicity and Efficacy Endpoints · SiM · 2025-05-19 · 在第 19 页
- TODO: A Triple‐Outcome Double‐Criterion Optimal Design for Dose Monitoring‐and‐Optimization in Multi‐Dose Randomized Trials · SiM · 2025-05-19 · 在第 19 页
- Sample Size and Power Calculations With Win Measures Based on Hierarchical Endpoints · SiM · 2025-05-19 · 在第 19 页
- Sample Size Calculation in Dose Optimization Trials Using the Margin of Practical Non‐Inferiority · SiM · 2025-05-19 · 在第 19 页
- Inference for Cumulative Incidences and Treatment Effects in Randomized Controlled Trials With Time‐to‐Event Outcomes Under ICH E9 (R1) · SiM · 2025-05-19 · 在第 19 页
- Closed MCP‐Mod for Pairwise Comparisons of Several Doses With a Control · SiM · 2025-05-19 · 在第 19 页
- COMIC: A Bayesian Dose Optimization Design for Drug Combination in Multiple Indications With Application to CAR‐T Therapies · SiM · 2025-05-19 · 在第 19 页
- Bayesian Estimation of Hierarchical Linear Models From Incomplete Data: Cluster‐Level Interaction Effects and Small Sample Sizes · SiM · 2025-05-16 · 在第 19 页
- Accounting for Inconsistent Use of Covariate Adjustment in Group Sequential Trials · SiM · 2025-05-16 · 在第 19 页
- A model-free phase I/II dose optimization design for immunotherapy trials · SMMR · 2025-05-15 · 在第 19 页
- Rank-based estimators of global treatment effects for cluster randomized trials with multiple endpoints on different scales · SMMR · 2025-05-14 · 在第 19 页
- Permutation-based global rank test with adaptive weights for multiple primary endpoints · SMMR · 2025-05-14 · 在第 19 页
- Evaluating the sample size requirements of tree-based ensemble machine learning techniques for clinical risk prediction · SMMR · 2025-05-14 · 在第 19 页
- Analysis of recurrent events in cluster randomised trials: The PLEASANT trial case study · SMMR · 2025-05-14 · 在第 19 页
- A family of Bayesian prognostic and predictive covariate-adjusted response-adaptive randomization designs · SMMR · 2025-05-14 · 在第 19 页
- Partial areas under the curve of the cumulative distribution function as a new composite estimand for randomized clinical trials · SMMR · 2025-04-28 · 在第 20 页
- Identifying Less Burdensome and More Cost‐Efficient Incomplete Stepped Wedge Designs for Continuous Outcomes Collected via Repeated Cross‐Sections · SiM · 2025-04-25 · 在第 20 页
- Design and Analysis of Pragmatic Trials by Song Zhang, Chul Ahn, Hong Zhu, Chapman and Hall/CRC, 2023, ISBN: 9781003126010https://www.routledge.com/Design-and-Analysis-of-Pragmatic-Trials/Zhang-Ahn-Zhu/p/book/9781003126010 · Biometrics · 2025-04-18 · 在第 20 页
- An Economical Approach to Design Posterior Analyses · JASA · 2025-04-16 · 在第 20 页
- Instrumental Variable Methods to Target Hypothetical Estimands With Longitudinal Repeated Measures Data: Application to the STEP 1 Trial · SiM · 2025-04-11 · 在第 21 页
- A Generalized Phase I/II Dose Optimization Trial Design With Multi‐Categorical and Multi‐Graded Outcomes · SiM · 2025-04-11 · 在第 21 页
- Analysis of Covariance in General Factorial Designs Through Multiple Contrast Tests Under Variance Heteroscedasticity · SiM · 2025-04-09 · 在第 21 页
- A Robust Score Test in G‐Computation for Covariate Adjustment in Randomized Clinical Trials Leveraging Different Variance Estimators via Influence Functions · SiM · 2025-04-08 · 在第 21 页
- Estimand-based inference in the presence of long-term survivors · SMMR · 2025-03-31 · 在第 22 页
- Dose selection criteria to identify the optimal dose based on ranked efficacy-toxicity outcomes without reliance on clinical utilities · SMMR · 2025-03-31 · 在第 22 页
- Using shrinkage methods to estimate treatment effects in overlapping subgroups in randomized clinical trials with a time-to-event endpoint · SMMR · 2025-03-25 · 在第 22 页
- Sequential Monitoring of Covariate‐Adaptive Randomized Clinical Trials With Non‐Parametric Approaches · SiM · 2025-03-20 · 在第 23 页
- Sample size determinations in four-level longitudinal cluster randomized trials with random slope · SMMR · 2025-03-20 · 在第 23 页
- Optimal treatment regime estimation in practice: challenges and choices in a randomized clinical trial for depression · Biometrics · 2025-03-20 · 在第 23 页
- On estimation of overall treatment effects in multiregional clinical trials under a discrete random effects model · SMMR · 2025-03-20 · 在第 23 页
- How to add baskets to an ongoing basket trial with information borrowing · SMMR · 2025-03-20 · 在第 23 页
- A connection between covariate adjustment and stratified randomization in randomized clinical trials · SMMR · 2025-03-20 · 在第 23 页
- Identification and Estimation of Causal Effects Using Non‐Concurrent Controls in Platform Trials · SiM · 2025-03-17 · 在第 23 页
- Adaptive Weight Selection for Time‐To‐Event Data Under Non‐Proportional Hazards · SiM · 2025-03-17 · 在第 23 页
- Preservation of Type I Error for Partially‐Unblinded Sample Size Re‐Estimation · SiM · 2025-03-14 · 在第 23 页
- Combining covariate adjustment with group sequential, information-adaptive designs to improve randomized trial efficiency · Biometrics · 2025-03-10 · 在第 24 页
- Addressing selection bias in cluster randomized experiments via weighting · Biometrics · 2025-03-07 · 在第 24 页
- Active‐Controlled Trial Design for HIV Prevention Trials With a Counterfactual Placebo · SiM · 2025-03-05 · 在第 24 页
- A Seamless Design for the Combination of a Case–Control and a Cohort Diagnostic Accuracy Study · SiM · 2025-03-05 · 在第 24 页
- A Novel Approach to Assess the Predictiveness of a Continuous Biomarker in Early Phases of Drug Development · SiM · 2025-02-25 · 在第 24 页
- Potential outcome simulation for efficient head-to-head comparison of adaptive dose-finding designs · Biometrics · 2025-02-24 · 在第 24 页
- Extension of Fisher’s least significant difference method to multi-armed group-sequential response-adaptive designs · SMMR · 2025-02-24 · 在第 24 页
- A Comparison of Statistical Methods for Time‐To‐Event Analyses in Randomized Controlled Trials Under Non‐Proportional Hazards · SiM · 2025-02-20 · 在第 25 页
- Bayesian Hierarchical Penalized Spline Models for Immediate and Time‐Varying Intervention Effects in Stepped Wedge Cluster Randomized Trials · SiM · 2025-02-18 · 在第 25 页
- Analysis of Cohort Stepped Wedge Cluster‐Randomized Trials With Nonignorable Dropout via Joint Modeling · SiM · 2025-02-18 · 在第 25 页
- Combining experimental and observational data through a power likelihood · Biometrics · 2025-02-17 · 在第 25 页
- The relative efficiency of staircase and stepped wedge cluster randomised trial designs · SMMR · 2025-02-16 · 在第 25 页
- Using Win Odds to Improve Commit‐to‐Phase‐3 Decision‐Making in Oncology · SiM · 2025-02-14 · 在第 25 页
- Power and Sample Size Calculations for Cluster Randomized Hybrid Type 2 Effectiveness‐Implementation Studies · SiM · 2025-02-10 · 在第 26 页
- RMST for Interval‐Censored Data in Oncology Clinical Trials · SiM · 2025-02-08 · 在第 26 页
- DOD ‐ SSR : An Adaptive Seamless Phase II / III Design With Dose Optimization Decision and Sample Size Re‐estimation · SiM · 2025-02-07 · 在第 26 页
- Applying the Estimands Framework to Non‐Inferiority Trials: Guidance on Choice of Hypothetical Estimands for Non‐Adherence and Comparison of Estimation Methods · SiM · 2025-02-07 · 在第 26 页
- Estimating Average Treatment Effects With Support Vector Machines · SiM · 2025-02-06 · 在第 26 页
- A General Framework to Assess Complex Heterogeneity in the Strength of a Surrogate Marker · SiM · 2025-02-06 · 在第 26 页
- Estimating hypothetical estimands with causal inference and missing data estimators in a diabetes trial case study · Biometrics · 2025-01-28 · 在第 27 页
- Improving the Effectiveness of Sample Size Re‐Estimation: An Operating Characteristic Focused, Hybrid Frequentist‐Bayesian Approach · SiM · 2025-01-25 · 在第 27 页
- Sample Size Adjustment in Sequential Multiple Assignment Randomized Trials · SiM · 2025-01-24 · 在第 27 页
- Reference‐Based Multiple Imputation for Longitudinal Binary Data · SiM · 2025-01-24 · 在第 27 页
- On Inclusion of Covariates in Model Based Dose Finding Clinical Trial Designs · SiM · 2025-01-24 · 在第 27 页
- Matching‐Assisted Power Prior for Incorporating Real‐World Data in Randomized Clinical Trial Analysis · SiM · 2025-01-22 · 在第 28 页
- The effect of estimating prevalences on the population-wise error rate · SMMR · 2025-01-19 · 在第 28 页
- Group sequential design using restricted mean survival time as the primary endpoint in clinical trials · SMMR · 2025-01-19 · 在第 28 页
- Estimating target population treatment effects in meta-analysis with individual participant-level data · SMMR · 2025-01-19 · 在第 28 页
- Efficient estimation of the marginal mean of recurrent events in randomized controlled trials · SMMR · 2025-01-19 · 在第 28 页
- Using circulating tumor DNA as a novel biomarker of efficacy for dose-finding designs in oncology · SMMR · 2025 · 在第 29 页
- Sketching in High-Dimensional Regression With Big Data Using Gaussian Scale Mixture Priors · JMLR · 2025 · 在第 30 页